These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 21518686

  • 1. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
    Briguori C, Visconti G, Ricciardelli B, Condorelli G, REMEDIAL II Investigators.
    EuroIntervention; 2011 Apr; 6(9):1117-22, 7. PubMed ID: 21518686
    [Abstract] [Full Text] [Related]

  • 2. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
    Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G, REMEDIAL II Investigators.
    Circulation; 2011 Sep 13; 124(11):1260-9. PubMed ID: 21844075
    [Abstract] [Full Text] [Related]

  • 3. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A.
    Circulation; 2007 Mar 13; 115(10):1211-7. PubMed ID: 17309916
    [Abstract] [Full Text] [Related]

  • 4. Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation).
    Barbanti M, Gulino S, Capranzano P, Immè S, Sgroi C, Tamburino C, Ohno Y, Attizzani GF, Patanè M, Sicuso R, Pilato G, Di Landro A, Todaro D, Di Simone E, Picci A, Giannetto G, Costa G, Deste W, Giannazzo D, Grasso C, Capodanno D, Tamburino C.
    JACC Cardiovasc Interv; 2015 Oct 13; 8(12):1595-604. PubMed ID: 26386766
    [Abstract] [Full Text] [Related]

  • 5. Renalguard system in high-risk patients for contrast-induced acute kidney injury.
    Briguori C.
    Minerva Cardioangiol; 2012 Jun 13; 60(3):291-7. PubMed ID: 22653043
    [Abstract] [Full Text] [Related]

  • 6. RenalGuard system in high-risk patients for contrast-induced acute kidney injury.
    Briguori C, Visconti G, Donahue M, De Micco F, Focaccio A, Golia B, Signoriello G, Ciardiello C, Donnarumma E, Condorelli G.
    Am Heart J; 2016 Mar 13; 173():67-76. PubMed ID: 26920598
    [Abstract] [Full Text] [Related]

  • 7. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
    Hafiz AM, Jan MF, Mori N, Shaikh F, Wallach J, Bajwa T, Allaqaband S.
    Catheter Cardiovasc Interv; 2012 May 01; 79(6):929-37. PubMed ID: 21542114
    [Abstract] [Full Text] [Related]

  • 8. Renal insufficiency following contrast media administration trial III: Urine flow rate-guided versus left-ventricular end-diastolic pressure-guided hydration in high-risk patients for contrast-induced acute kidney injury. Rationale and design.
    Briguori C, D'Amore C, De Micco F, Signore N, Esposito G, Napolitano G, Focaccio A, REMEDIAL III Investigators.
    Catheter Cardiovasc Interv; 2020 Apr 01; 95(5):895-903. PubMed ID: 31282129
    [Abstract] [Full Text] [Related]

  • 9. Prevention of postcontrast acute kidney injury after percutaneous transluminal angioplasty by inducing RenalGuard controlled furosemide forced diuresis with matched hydration: study protocol for a randomised controlled trial.
    Bolt LJJ, Sigterman TA, Krasznai AG, Sikkink CJM, Schurink GH, Bouwman LH.
    BMJ Open; 2018 Oct 04; 8(9):e021842. PubMed ID: 30287607
    [Abstract] [Full Text] [Related]

  • 10. The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Bolognese L, Falsini G, Grotti S, Limbruno U, Liistro F, Carrera A, Angioli P, Picchi A, Ducci K, Pierli C.
    J Cardiovasc Med (Hagerstown); 2010 Mar 04; 11(3):199-206. PubMed ID: 19829124
    [Abstract] [Full Text] [Related]

  • 11. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial.
    Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, Mansournia MA, Yamini-Sharif A, Amirzadegan A, Salarifar M, Sadeghian S, Davoodi G, Borumand MA, Esfehani FA, Darabian S.
    Am J Kidney Dis; 2009 Oct 04; 54(4):610-8. PubMed ID: 19619921
    [Abstract] [Full Text] [Related]

  • 12. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E, Poh KK, Lu Q, Zhang JJ, Tan N, Hou XM, Ong HY, Azan A, Chen SL, Chen JY, Ali RM, Fang WY, Lau TW, Tan HC.
    Int J Cardiol; 2015 Dec 15; 201():237-42. PubMed ID: 26301645
    [Abstract] [Full Text] [Related]

  • 13. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, Focaccio A, Montorfano M, Carlino M, Condorelli G, Ricciardelli B.
    Kidney Int; 2005 Nov 15; 68(5):2250-5. PubMed ID: 16221226
    [Abstract] [Full Text] [Related]

  • 14. RenalGuard system to prevent contrast-induced acute kidney injury in Japanese patients with renal dysfunction; RESPECT KIDNEY study.
    Katoh H, Nozue T, Horie K, Sozu T, Inoue N, Michishita I.
    Cardiovasc Interv Ther; 2019 Apr 15; 34(2):105-112. PubMed ID: 29730853
    [Abstract] [Full Text] [Related]

  • 15. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy.
    Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, Schneider H, Koerber T, Ince H, Steiner M, Schuff-Werner P, Nienaber CA.
    Coron Artery Dis; 2008 Sep 15; 19(6):413-9. PubMed ID: 18955835
    [Abstract] [Full Text] [Related]

  • 16. Prevention of Contrast-Induced Acute Kidney Injury by Furosemide With Matched Hydration in Patients Undergoing Interventional Procedures: A Systematic Review and Meta-Analysis of Randomized Trials.
    Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, Pedrazzini G.
    JACC Cardiovasc Interv; 2017 Feb 27; 10(4):355-363. PubMed ID: 28231903
    [Abstract] [Full Text] [Related]

  • 17. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N, Lanzi L, Garante CM, Tersigni F, Sergiacomi R, Petrassi M, Di Matteo A, Tufano F.
    Eur Rev Med Pharmacol Sci; 2013 Feb 27; 17 Suppl 1():13-21. PubMed ID: 23436661
    [Abstract] [Full Text] [Related]

  • 18. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F, Formica M.
    G Ital Nefrol; 2002 Feb 27; 19(5):529-33. PubMed ID: 12439841
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M, Cengiz H, Hoeltgen R, Wieczorek M, Boedeker RH, Scheibelhut C, Boening A.
    J Invasive Cardiol; 2013 Jun 27; 25(6):276-83. PubMed ID: 23735352
    [Abstract] [Full Text] [Related]

  • 20. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, Liistro F, Carrera A, Angioli P, Picchi A, Ducci K, Pierli C.
    Am J Cardiol; 2012 Jan 01; 109(1):67-74. PubMed ID: 21943940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.